Gene sequence construct for gene therapy of human immunodeficiency virus infection
US-2024352096-A1 · Oct 24, 2024 · US
Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US9951106B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9951106-B2 |
| Application number | US-201314649565-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 4, 2013 |
| Priority date | Dec 4, 2012 |
| Publication date | Apr 24, 2018 |
| Grant date | Apr 24, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.
First claim
Opening claim text (preview).
What is claimed is: 1. A polypeptide comprising the amino acid sequence set forth in SEQ ID NO:8, termed gp120-b12-ScFV. 2. An immunogenic formulation comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier and/or adjuvant. 3. A method of generating an immune response in a subject comprising administering an immunologically effective amount of an immunogenic formulation of claim 2 to a subject, thereby generating an immune response in a subject.
Assignees
Inventors
Classifications
- C07K16/1145Primary
Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title
Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes · CPC title
env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site · CPC title
Retroviridae, e.g. equine infectious anemia virus · CPC title
multispecific · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9951106B2 cover?
- Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.
- Who is the assignee on this patent?
- Guan Yongjun, Lewis George, Devico Anthony, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/1145. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).